Faron Pharmaceuticals OY (FARN) NPV
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
Faron Pharmaceuticals candidate gets FDA fast track designation
27 August 2024 13:00
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced on Tuesday that its lead candidate, bexmarilimab, has been granted fast track designation by the US Food and Drug...
-
Faron gets positive FDA feedback on bexmarilimab study plans
11 July 2024 11:48
(Sharecast News) - Faron Pharmaceuticals announced positive feedback from the FDA regarding the clinical development plan for its drug candidate bexmarilimab, aimed at treating myelodysplastic syndrome...
-
Faron Pharmaceuticals extends funding agreement with IPF
30 April 2024 16:33
(Sharecast News) - Faron Pharmaceuticals announced on Tuesday that it has extended its agreement with lender IPF to ensure continued financial support as it progressed towards securing longer-term funding.
-
Faron Pharmaceuticals CFO stands down
15 April 2024 09:36
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals revealed on Monday that chief financial officer James O'Brien would be leaving the group to "pursue another career...
-
Faron Pharmaceuticals taps Juho Jalkanen for CEO
8 April 2024 09:17
(Sharecast News) - Biopharmaceutical company Faron Pharmaceuticals named Dr Juho Jalkanen as its next chief executive officer on Monday.
-
Faron shares jump on encouraging trial data
18 March 2024 14:14
(Sharecast News) - Faron Pharmaceuticals announced further encouraging data from the first phase of its 'BEXMAB' trial on Monday, targeting higher-risk (HR) myelodysplastic syndrome (MDS) patients...
-
Faron Pharmaceuticals reports year of clinical progress
13 March 2024 11:52
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals reported a year of strong progress on Wednesday, with significant overall response rates seen in both previously...
-
Faron Pharmaceuticals shores up cash with EUR 3.2m convertible loans
4 March 2024 10:40
(Sharecast News) - Faron Pharmaceuticals announced on Monday that it has successfully secured binding commitments for convertible loans totalling €3.2m from a select group of existing shareholders.
-
Faron launches second phase of leukaemia treatment trial
9 January 2024 12:36
(Sharecast News) - Faron Pharmaceuticals has initiated phase two of the BEXMAB trial, it announced on Tuesday, marking a significant milestone in its cancer treatment development programme.
-
Faron unveils promising antibody study results
11 December 2023 13:22
(Sharecast News) - Faron Pharmaceuticals unveiled promising phase one data from its BEXMAB study in myeloid malignancies during the 65th American Society of Hematology (ASH) annual meeting, it announced on...
-
Faron publishes cancer immunotherapy study findings
7 December 2023 11:01
(Sharecast News) - Faron Pharmaceuticals announced the publication of the comprehensive findings from the groundbreaking phase one and two 'MATINS' trial of bexmarilimab on Thursday - its humanised...
-
Faron reveals details of next stage of bexmarilimab study
6 November 2023 10:31
(Sharecast News) - Faron Pharmaceuticals announced on Monday that, following guidance from the US Food and Drug Administration (FDA), the initial indication for phase two advancement in the study...
Company announcements Announcements
-
Grant of options
30 August 2024 07:00
Faron Pharmaceuticals Oy (DI)
-
FDA Grants Fast Track Designation for Bexmarilimab
27 August 2024 07:00
Faron Pharmaceuticals Oy (DI)
-
Faron 2024 Half-Year Financial Results
27 August 2024 07:00
Faron Pharmaceuticals Oy (DI)
-
Notice of Half-Year Financial Results
20 August 2024 07:00
Faron Pharmaceuticals Oy (DI)
-
Appointment of Chief Financial Officer
8 August 2024 07:00
Faron Pharmaceuticals Oy (DI)
-
Grant of options
7 August 2024 10:00
Faron Pharmaceuticals Oy (DI)
-
Faron Appoints Dr. Petri Bono as new CMO
6 August 2024 08:30
Faron Pharmaceuticals Oy (DI)
-
Faron Announces Positive FDA Feedback
11 July 2024 07:00
Faron Pharmaceuticals Oy (DI)
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.